Ranibizumab Biosimilar - Research Grade

Giannos, S.A et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharm Res, 2024, 41, 1247–1256.

Human

VEGF

>1mg/ml

Human IgG1 Kappa

Humanized

Bevacizumab Biosimilar - Research Grade (ICH4003), Aflibercept Biosimilar - Research Grade (ICH4015), Brolucizumab Biosimilar - Research Grade (ICH5197), Suvemcitug Biosimilar - Research Grade (ICH5889), Tarcocimab Biosimilar - Research Grade (ICH5901), Varisacumab Biosimilar - Research Grade (ICH5969)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P15692

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of ranibizumab, an anti-VEGF-A biologic, supplied strictly for research use only. It is built to recognise human vascular endothelial growth factor A (VEGF-A, UniProt P15692) and reproduces the target-binding behaviour of the originator so investigators can use it as a defined reference reagent rather than as a clinical product. Note that clinical ranibizumab is an antigen-binding fragment (Fab) rather than a full antibody; this research-grade analog is offered as a human IgG1 kappa format for laboratory work, so users studying Fab-specific properties should confirm the format suits their assay. Typical applications include VEGF-A neutralisation and binding studies, isotype/positive controls, standard curves, benchmarking of biosimilar or novel anti-VEGF candidates, and preclinical in-vitro angiogenesis models. It is manufactured at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities to support screening and scale-up. It is not the clinical drug and is not for human or veterinary use. VEGF-A (UniProt P15692) is the prototypic member of the vascular endothelial growth factor family and the principal driver of physiological and pathological angiogenesis. It is a secreted, disulphide-linked homodimeric glycoprotein produced as several splice isoforms (for example VEGF121, VEGF165, VEGF189) that differ in heparin and neuropilin binding. VEGF-A signals mainly through the receptor tyrosine kinases VEGFR-1 (FLT1) and VEGFR-2 (KDR), with VEGFR-2 mediating most pro-angiogenic effects, promoting endothelial proliferation, migration, survival and vascular permeability. Hypoxia, via HIF-1alpha, is a key inducer of VEGF-A expression. Dysregulated VEGF-A underlies neovascular (wet) age-related macular degeneration, diabetic macular oedema, retinal vein occlusion and tumour angiogenesis, which is why VEGF-A neutralisation is a central therapeutic and research strategy.

Vascular endothelial growth factor

Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ranibizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Ranibizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Ranibizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ranibizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ranibizumab that binds human VEGF.